SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-08-260208
Filing Date
2008-12-24
Accepted
2008-12-24 16:57:12
Documents
5
Period of Report
2008-12-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d8k.htm 8-K 28270
2 CONTINGENT VALUE RIGHTS AGREEMENT dex101.htm EX-10.1 73251
3 LIGAND PHARMACEUTICALS INCORPORATED AMENDED AND RESTATED SEVERANCE PLAN dex102.htm EX-10.2 47812
4 PRESS RELEASE dex991.htm EX-99.1 7659
5 GRAPHIC g39830g55e13.jpg GRAPHIC 3104
  Complete submission text file 0001193125-08-260208.txt   163178
Mailing Address 10275 SCIENCE CENTER DRIVE SAN DIEGO CA 92121-1117
Business Address 10275 SCIENCE CENTER DRIVE SAN DIEGO CA 92121-1117 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

IRS No.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33093 | Film No.: 081270743
SIC: 2834 Pharmaceutical Preparations